Excitement Over MS Stem Cell Transplant 'Game Changer' Data
Executive Summary
An international trial has demonstrated that HSCT was more effective than standard drugs for people with highly active relapsing-remitting multiple sclerosis. Also a one-off transplant compared to lifelong therapy has considerable cost-saving implications.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.